RayKnowChina Research Map
Shortlist

RecruitingCoronary heart diseasePhase 4

Registered title, quoted from ClinicalTrials.gov

Precision Colchicine Intervention to Suppress Atherosclerosis in TET2 Clonal Hematopoiesis

An open trial on coronary heart disease, registered on ClinicalTrials.gov. Led by Shenyang Northern Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorShenyang Northern HospitalShenyangHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07362966, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 40 years to 85 years; sex: all

    Registered eligibility fields

  2. Colchicine use within 30 days prior to randomization, or planned colchicine therapy for other indications;

    Exclusion criterion 12

  3. Abnormal liver function (ALT >3 times the upper limit of normal range) at randomization;

    Exclusion criterion 5

    Abnormal renal function (serum creatinine >1.5 times the upper limit of normal range or estimated eGFR <45 mL/min/1.73 m²) at randomization;

    Exclusion criterion 6

    Hematologic abnormalities: anemia (hemoglobin <100g/L), thrombocytopenia (platelet count <100×109/L) or leukopenia (white blood cell <3×109/L) at randomization;

    Exclusion criterion 7

  4. Current or planned use of any of cyclosporine, verapamil, HIV protease inhibitors, azole antifungals, or macrolide antibiotics;

    Exclusion criterion 13

  5. Pregnancy, breastfeeding, or women of childbearing potential who are not using an effective method of contraception;

    Exclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07362966, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age 40-85 years;
  • Patients with recent hospitalization for documented ACS (the index event occurring 30-90 days before randomization) and meeting all of the following:
  • During the index hospitalization, patients underwent either PCI or diagnostic coronary angiography alone,
  • At least one non-culprit coronary lesion with 30%-70% diameter stenosis by visual estimation on coronary angiography,
  • Clinically stable throughout the screening period,
  • Receiving standard of care therapy for ACS in accordance with national guidelines,
  • Peripheral blood DNA available for targeted sequencing, with results demonstrating either TET2-CHIP or no CHIP-associated variants;
  • Written informed consent.

Exclusion Criteria:

  • Prior coronary artery bypass grafting (CABG) before documented ACS;
  • Other clinically significant cardiovascular diseases, including moderate-to-severe valvular heart disease (moderate or severe), heart failure (NYHA class III-IV), or atrial fibrillation;
  • Non-culprit coronary anatomy (e.g., marked tortuosity, bifurcation lesions, or small vessels <1.5 mm in diameter) deemed to preclude plaque assessment by CCTA;
  • Planned PCI or CABG;
  • Abnormal liver function (ALT >3 times the upper limit of normal range) at randomization;
  • Abnormal renal function (serum creatinine >1.5 times the upper limit of normal range or estimated eGFR <45 mL/min/1.73 m²) at randomization;
  • Hematologic abnormalities: anemia (hemoglobin <100g/L), thrombocytopenia (platelet count <100×109/L) or leukopenia (white blood cell <3×109/L) at randomization;
  • Inflammatory bowel disease (Crohn's or ulcerative colitis) or active diarrhea;
  • Symptomatic peripheral neuropathy, pre-existing progressive neuromuscular disease or creatine kinase (CK) level > 3 times the upper limit of normal range as measured within the past 30 days and determined to be non-transient through repeat testing;
  • Pregnancy, breastfeeding, or women of childbearing potential who are not using an effective method of contraception;
  • Any contraindication, known allergy or intolerance to colchicine;
  • Colchicine use within 30 days prior to randomization, or planned colchicine therapy for other indications;
  • Current or planned use of any of cyclosporine, verapamil, HIV protease inhibitors, azole antifungals, or macrolide antibiotics;
  • Existing or planned treatment with other anti-inflammatory or immunosuppressive drugs;
  • History of malignancy (hematologic or solid-tumor);
  • History of transplantation (hematopoietic stem cell or solid-organ);
  • Significant radiation exposure (≥40 mSv) within the past 12 months;
  • Known hypersensitivity to iodinated contrast media or uncontrolled active hyperthyroidism;
  • Current enrollment in another clinical trial;
  • A predicted life expectancy < 1 year;
  • Any other circumstances in which the investigator judges that the patient is not suitable to participate in the clinical trial.

Quoted from ClinicalTrials.gov, NCT07362966, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07362966, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07362966